The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...
Plasma IQ is the latest advancement in aesthetics and the first FDA Class II cleared handheld plasma device. The device delivers focused, controlled plasma energy to safely and effectively create ...
FibroBiologics files a new USPTO patent covering its fibroblast-based platform for disc repair, cartilage restoration, and ...
The aggregate gross proceeds to the Company from the offering were approximately $1.7 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The ...
Background Intestinal fibrosis, a hallmark complication of Crohn’s disease (CD), frequently progresses to stricture formation ...
Platform Poised to Expand into Joint and Cartilage RepairHOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage ...
This article is based on a poster originally authored by Fiona Leslie, Chloe Whiting, and Megan Webster. TGF-β1-mediated activation of fibroblasts, their transition to α-SMA-expressing myofibroblasts, ...
TipRanks on MSN
FibroBiologics submits new patent application with USPTO
FibroBiologics (FBLG) announced that it has submitted a new patent application with the U.S. Patent and Trademark Office, USPTO, titled “Spheroids ...
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback